Delving into the Latest Updates on Instytut Matki I Dziecka with Synapse

概览

关联

6

项与 Instytut Matki I Dziecka 相关的临床试验

CTIS2023-508643-46-00 / Recruiting

Comparison of the efficacy and safety of valaciclovir in the prevention of transmission and treatment of intrauterine infection in pregnant women with primary cytomegalovirus infection depending on the used drug dose - the first Polish non-commercial non-inferiority clinical trial. - POL PRENATAL CMV

开始日期2024-08-14

申办/合作机构

Instytut Matki I Dziecka

CTIS2024-515805-25-00 / Recruiting

Optimalization Of The Time And Dosage Of Vemurafenib In BRAF Positive Juvenile Patients With Refractory Histiocytosis - BRAVO

开始日期2021-05-13

申办/合作机构

Instytut Matki I Dziecka

CTIS2024-515896-37-00 / Recruiting

Optimalization Of The Time And Dosage Of Trametinib In BRAF Negative Juvenile Patients With Refractory Histiocytosis Or After Failure Of Vemurafenib Treatment. - TRAM

开始日期2021-04-20

申办/合作机构

Instytut Matki I Dziecka

100 项与 Instytut Matki I Dziecka 相关的临床结果

登录后查看更多信息

0 项与 Instytut Matki I Dziecka 相关的专利（医药）

登录后查看更多信息

523

项与 Instytut Matki I Dziecka 相关的文献（医药）

2021-10-01·Journal of the American Society of Nephrology

PO0224

作者: Klimm, Wojciech ; Szamotulska, Katarzyna ; Niemczyk, Stanislaw ; Wozniak-Kosek, Agnieszka

2019-01-01·Developmental period medicine

[25 years of work: The Interdisciplinary Team for Fetal Malformation at the Institute of Mother and Child in Warsaw - from counselling to clinical ethics].

Article

作者: Jaczyńska, Renata ; Helwich, Ewa ; Szczepaniak, Sławomir ; Rutkowska, Magdalena ; Reśko-Zachara, Marzanna ; Maciejewski, Tomasz Mikołaj

Perinatology is a dynamically developing field of medicine. The progress of technology in recent decades has made it possible to recognize birth defects very early, including those which are lethal or genetically determined. In many clinical situations, it is no longer possible to work alone to reach a definitive diagnosis, plan treatment or predict the clinical course of the affected fetus/newborn. There is a need for teamwork, which ensures the proper, early care starting in the fetal period, not only in the delivery room or NICU. This paper discusses the ethical foundations of creating interdisciplinary teams, taking as an example the Interdisciplinary Team for Fetal Malformation at the Institute of Mother and Child in Warsaw, which has been active for 25 years, and presents how it works in practice. On the basis of the clinical cases that are examined, practical guidelines were formulated for both the work of medical teams and the way parents are informed about the clinical situation of their child and about sharing the care after the birth of the child. A document was also proposed with information on prenatal diagnosis, decisions made by the interdisciplinary team regarding the mother and child, as well as the conclusions resulting from discussions with parents.

2018-09-01·Pediatrics2区 · 医学

Efficacy of Propranolol Between 6 and 12 Months of Age in High-Risk Infantile Hemangioma

2区 · 医学

Article

作者: Delarue, Alain ; Bouroubi, Athmane ; Baselga, Eulalia ; Lebbé, Geneviève ; Voisard, Jean-Jacques ; Przewratil, Przemysław ; Zaim, Mohammed ; Gautier, Stéphanie ; Dembowska-Baginska, Bozenna ; González-Enseñat, María Antonia ; Menon, Yoann ; Wyrzykowski, Dariusz ; Esteve-Martinez, Altea ; Rychłowska-Pruszyńska, Magdalena ; Torrelo, Antonio ; López Gutiérrez, Juan-Carlos ; Roé, Esther ; de Lucas-Laguna, Raúl

BACKGROUND AND OBJECTIVES:There is no consensus on optimal treatment duration for propranolol in infantile hemangioma (IH). We evaluated the efficacy and safety of oral propranolol solution administered for a minimum of 6 months up to a maximum of 12 months of age in high-risk IH.METHODS:This single-arm, open-label, phase 3 study was conducted in patients aged 35 to 150 days with high-risk IH in 10 hospitals between 2015 and 2017. The study comprised a 6-month initial treatment period (ITP) plus continuation up to 12 months of age if complete success was not achieved, a follow-up, and a retreatment period. Patients received oral propranolol twice daily (3 mg/kg per day). The primary end point was the success rate at the end of the ITP. Furthermore, the persistence of IH response and efficacy of retreatment was evaluated.RESULTS:The success rate after 6 months of treatment was 47%, increasing to 76% at the end of the ITP. Of the patients who achieved success, 68% sustained success for 3 months without treatment, and 24% required retreatment. Of the 8 patients who were retreated, 7 achieved success. Adverse events, reported by 80% of patients, were mild, which were expected in this population or known propranolol side effects.CONCLUSIONS:Oral propranolol administered beyond 6 months and up to 12 months of age meaningfully increases the success rate in high-risk IH. Success was sustained in most patients up to 3 months after stopping treatment. Retreatment was efficacious, and the safety profile satisfactory.

100 项与 Instytut Matki I Dziecka 相关的药物交易

登录后查看更多信息

100 项与 Instytut Matki I Dziecka 相关的转化医学

登录后查看更多信息